



BioSystems International announces appointment of a new CEO

Evry, France – March 12, 2007 – Jean-Pierre Tirouflet joins BioSystems International as CEO.

BioSystems International ("BSI") is a French biotechnology company with research laboratories in France (Genopole-Evry) and Hungary (University of Debrecen). BSI's business is focused on the discovery and diagnostic development of biomarkers, based on its proprietary high throughput monoclonal antibody technology.

Prior to joining BSI, Jean-Pierre Tirouflet was Chairman and CEO of the French specialty chemicals company Rhodia. He was Chief Financial Officer of Rhône Poulenc from 1986 to 1997 and member of its Executive Board from 1990 to 1999. Mr Tirouflet has been Chairman of the CEFIC (European Chemical Industry Council) from 2002 to 2004.

Formerly, he worked for the French Ministry of Finances, the French Representation to the EEC and the Crédit National. He is a graduate of France's Ecole Nationale d'Administration.

About BioSystems International:

The mission of BioSystems International is to bring biomarkers to the bedside

BioSystems International is a biotechnology company and is the industry leader in monoclonal antibody mediated biomarker discovery and diagnostics development. Its leading position in the field is secured by a proprietary, high throughput monoclonal antibody based platform that achieves biomarker discovery and the first level of validation in one step. It aims at bringing biomarkers to the bedside in record time and at delivering integrated and new companion diagnostics for the chronic diseases and cancer markets

BSI was founded in May 2004 by four internationally recognized American scientists, the Professors Barry Karger and William Hancock of Northeastern University of Boston, Professor Andras Guttman and Dr. Laszlo Takacs. Until May 2004, Dr. Takacs was Head of Pfizer's former Fresnes Genomic and Bioinformatics laboratories. BSI's core research team is staffed with scientists from Dr. Takacs' prior Pfizer Fresnes group.

Since its founding, BSI has been principally financed by Societe Generale Asset Management by a grant from the Hungarian Ministry of Education.. www.biosys-intl.com

Contact :

François Liebaert

BioSystems International

4, rue Pierre Fontaine - 91058 Evry cedex - France

+33 1 60 87 89 32 / +33 6 85 32 93 58

francois.liebaert@biosys-intl.com

www.biosys-intl.com

About Genopole® :

GENOPOLE® is France's leading biopark dedicated to biotech & genetics research. It brings together private- and academic labs, biotech companies and higher education facilities (the University of Evry Val d'Essonne) on a 90,000-square meter site. With 23 research labs on campus and a portfolio of over 60 biotech firms, therapeutic innovation is a key concern for Genopole® stakeholders. Genopole®'s objective is to promote research in genomics, postgenomics and related sciences; reinforce technology transfer to the industrial sector; develop high-level life science training & education programs and, lastly, to create and nurture biotech companies.

www.genopole.fr